been reported to range between 25-80 mg/di [4] , with more than 90% occurring in the density range !.063-1.25 g/ml [3, 5] . in man, ApoA-ll mainly consists of two identical polypeptide chains of M r 87(}7 covalently linked by a disulfide bond between the cysteine residues at position 6 [!,6] ; it occurs, however, in smaller amounts in its monomeric form and as a heterodimer with ApoE [6, 7] . Like ApoA-I, ApoA-il is a secretory protein synthesized as a larger precursor (preproprotein) containing a prepeptide and a signal peptidc with 18 and five amino acid residues, respectively [8] , Whereas the cleavage of prepeptide occurs intracellularly, the conversion of proprotein to mature ApoA-II mainly occurs extracellularly in a reaction catalyzed by a procathepsin B-like proteinase [6, 9] .
ApoA-ll exists in plasma [n several polymorphic forms [10, 11] , Due to its high lipid-binding affinity, ApoA-ll plays a significant role in the formation and structural stability of HDL particles [12] [13] [14] [15] [16] . It has been suggested from in vitro expe~'iments that ApoA-II inhibits the activation of lecithin:cholestcrol acyltransferase by APOA-I [17] [18] [19] and modulates the activity of hegatic triglyceride lipase [20] [21] [22] . In a recent study, Carson has demonstrated that APOA-I! inhibits factor X activation by interfering with the association of t~zstte factor (coagulation factor lid with factor Vlla [23] .
A number of studies have demonstrated that HDL consist of several distinct iipoprotein particles differing with respect to their particles sizes, densities, chemical composition and metabolic properties [24] [25] [26] [27] . Among these lipoprotein particles identified and diff,:rentiated on the bas;s of their apotipoprotein composition [24] , ApoA-ll mainly occurs in association with ApoA-I as lipoprotein A-! :A-ll (LP-A-I :A-II) [28] [29] [30] [31] [32] [33] [34] . The LP-A-I:A-I] family is a polydisperse system of particles present throughout the HDL density range with the major part occurring in the HDL 3 subfraction [33, 35] . Another" lipoprotein form of ApoA-ll has been recently identified and characterized as lipoprotein All:B:C:D:E (LP-A-II:B:C:D:E (~r LP-A-II:B complex) in VLDL of patients with Tane.ier disease or phengtype V hyperlipoproteinemia [36] . There are also a few reports indicating the existence of LP-A-ll particles containing ApoA-I! as the major protein constituent but devoid of ApoA-I and ApoB and first detected in HDL of patients with Tan~.ier disease [37] . Subsequently, these particles have also been identified in low density lipoproteins (LDL) of a patient with APOA-I deficiency and planar xanthoma [38] , in HDL of normolipidemic subjects [39] and patients with visceral Leishmaniasis [40I.
The purpose of this study was to provide information on the concentration, composition and lipoprotein subspecies of LP-A-I! particles isolated by immtmoaffinity chromatography from whole plasma of normolipidemic subjects and to compare their properties with those of LP-A-ll particles isolated from patients with severe forms of APOA-I deficiency.
Materials and Methods

Subjects
Six normolipidemic subjects, two subjects homozygous and two subjects heterozygous for APOA-I/ ApoC-lll deficiency, two subjects homozygous and three subjects heterozygous for ApoA-I deficiency, and planar xanthoma and one subject homo~gous for Tangier disease were studied (Table I ). The normolipidemic subjects were healthy, asymptomatie Caucasians (two women and four men with a mean age of 47 _+ 14 years) without any history of familial hyperiipoproteinemia or diabetes mellitus. They were nonobese and non-smokers except for one subject consuming ten cigarettes per day. The alcohol consumption was below 50 g per week. One of the women was premcnopausal and the other was postmenopausal; the latter was taking Premarln (1.25 mg per day) and was characterized by very high levels of ApoA-! and ApoA-!I. The clinical features of two female patients with ApoA-I/ApoC-lll deficiency and their heterozygous relatives (patients' mother and .son of one of the patients) have been 9reviously reported [41] . Both homozygous patients had low levels of total cholesterol and triglycerides, very low levels of ApoA-ll and immunochemieally undetectable concentrations of ApoA-1 and ApoC-ilI. The heterozygous relatives also had low levels of total cholesterol and triglycerides. Their ApoA-I levels were between those of the patients and normals (Tabm !) and their ApoC-Ill concentrations (2.2 mg/dl) were approximately one-third to one-fourth of those considered normal for their age and sex (7.0 + 0.2 mg/dl for males aged 11-14 and 11.3 + 0.4 mg/dl foi females aged 51-601 [42] . In another kindred, two apparently homozygous patients and three of their relatives belong to a recently described variant of ApoA-i deficiency [43] . Clinically, both patients were characterized by planar xanthoma, xanthelasma and corneal opacities, but normal appearance of tonsils and no tendon xantnoma; one of the patients had a coronary bypass surgery when she was 58 years of age. Both patients hact moderately low levels of total cholesterol and normal levels of triglyceride (Table !) . The main biochemical abnormalities were the .severe deficiency, if not the absence, of ApoA-I and low concentrations of ApoA-ll, ApoC-I! (I.! and i.4 mg/dl), APOC-III (2.2 and 3.3 mg/dl) and ApoD (6.7 rag/all) but normal levels of ApoE (11.2 and 11.7 mg/dl). The apparently heterozygous relatives had normal concentrations of total cholesterol and triglycerides, but their levels of ApoA-! were more than one standard deviation below the normal mean values for their age and sex [42] ; the concentrations of ApoC peptides, ApoD and ApoE were in the upper normal range for their age and sex [42] , The clinical and biochemical features of the homozygous Tangier patient have been previously described [36] . None of the dyslipoproteinemic subjects was taking drugs known to influence lipid concentrations with the exception of patients with ApoA-I/ ApoC-lll deficiency who were treated daily with flblockers and soya lecithin.
Venous blood was drawn into EDTA-ccntaining Vacutainer tubes from normolipidemic and dyslipoproteinemic subjects after an overnight fast and the plasma samples were collected by low-speed centrifugation. Plasma samples collected at the Henry Ford Hospital, Detroit, MI (ApoA-I/ApoC-Ill deficiency), University Health Center, Ann Arbor, M! (ApoA-I deficiency) and Molecular Disease Branch, NIH, Bethesda, MD (Tangier disease) were immediately shipped ~.t 4°C and received in Oklahoma City, OK, the next morning. Upon receipt, preservatives were added to final concentrations of 500 units/ml penicillin-G, 50 ~g/ml streptomycin sulfate, 1.3 mg/ml e-amino caproie acid and 0.5 mg/ml reduced glutathione [44] . All blood donors signed written informed consents. The protocols were approved by the Institutional Review Boards.
Preparation o] hmmmosorber.~
To prepare immunosorbers, well-characterized "pan" monoelonal antibodies to ApoA-I [45] , ApoA-ll [36] and ApoB [46] Wel-~ coupled to the cross-linked agarose activated with N-hydroxysuccinimide (AffiGcl 111, BioRad, Richmond, CA) according to the previously described procedures [34, 47] . The binding capacities of the anti-ApoA-I, anti-ApoA-ll and anti-ApoB immunosorbers were 0.018 mg of ApoA-I, 0.U27 mg of APOA-I! and 0.052 mg of APOB per ml of gel, respectively. The immunosorbers were stable for more than 6 months at 4°C without loss of binding capacity.
Isolation of ApoA-H-containing lipoprotein particles
The fractionation of LP-A-I :A-II, LP-A-II : B complex and LP-A-II was performed by a recently described sequential, three-step immunoaffinity chromatography with anti-ApoA-ll, anti-ApoB and antiApoA-i immunosorbers [43] .
Crossed hnmunoelectrophoresis
Immunochemical characterization of LF-A-II particles was carried out by crossed immunoelectrophoresis performed according to a previously described procedure [40] using 1% agarose (lndubiose HA37, IBF Laboratories, Villeneuve-la-Garenne, France) as the supporting medium and a mixture (1 : I, v/v) of 0.06 M barbital buffer (pH 8.6) and Tris-HCl, EDTA and boric acid solutions (10.5; 0.50; 0.65 g/l), pH 9.(I. Starting material was either the ApoA-ll-containing lipoprotein particles (retained fraction from the anti-ApoA-ll immunosorber) or the isolated LP-A-il family (unretained fraction from the anti-ApoA-I immunosorber).
Lipid and apolipoprote#t analyses
Neutral lipids were quantified by the gas-liquid chromatographic procedure of Kuksis et al. [48] and the phospholipid phosphorus content was determined by the method of Gerlach and Deutieke [49] . Quantitative determination of apolipoproteins A-l, A-il, B, C-II, C-Ill, D and E was performed by electroim. munoassays developed in this laboratory and described in several previous reports [34, 36, 38, 47] . Monospecific, polyclonai antisera to apolipoproteins A-I, A-ll, B, C-II, C-Ill, D and E were prepared in rabbits and goats and characterized as previously described [50] .
Results
Pin,m, concentrations of ApoA.H associated with LP-A-I : A-II and LP.A-II particles
The fractionation of ApoA-ll-containing lipopro. teins was monitored by quantitative determination of ApoA-ll in all retained and unretained column fractions, The absolute values of ApoA-I! associated with LP-A-I! particles were calculated on the basis of plasma TAI~LE l! (Table I) . Although representing the onb ApoA-containing lipoprotein family in homozygous patients with either APOA-I/APOC-ill or APOA-i deficiencies, the mean concentrations of LP-A-ll particle: (7-13 mg/di) were only slightly higher than those ol normolipidemic subjects (Table I) normal subjects but essentially in the same range as those of homozygotes. Although in patients with Tangier disease the LP-A-Ii:B complex represented the major APOA-!I lipoprotein form [36] , a small but measurable concentration of LP-A-II particles was also detected confirming the previously reported presence of this lipoprotein family in Tangier disease [37] .
Lipid composition of LP-A-ll particles
Subjects Triglycerides
Lipid and apolipopro~ein composition of LP-A-H particles
The percent lipid composition of LP-A-ll particles from normolipidemic subjects, heterozygotes for APOA-I/ApoC-lll deficiency and a patient with Tangier disease was characterized by a negligible content of triglycerides, a very high content of phospholipids and a low ratio of cholesterol esters/free cholesterol (Table II) in comparison with the lipid composition of LP-A-I or LP-A-I:A-II particles [34] . In contrast, the lipid composition of LP-A-II from patients homozygous for either ApoA-I/ApoC-III or ApoA-I deft- ciency was characterized by increased percent contents of triglycerides and cholesterol esters and a decreased relative content of phospholipids (Table II) resembling the lipid composition of normal LP-A-I,A-ll and, especially, LP-A-I particles rather than that of normal LP-A-ll particles.
In some normolipidemic subjects ApoA-II was the only apolipoprotein constituent of LP-A-ll particles (Table liD . However, in most normolipidemie subjects including heterozygotes for ApoA-! deficiencies, ApoA-ll was found to be the major and ApoD the minor apolipoprotein. In contrast, the LP-A-II particles from homozygous patients with ApoA-I deficiencies contained ApoA-II, ApoE, APOD and ApoCpeptides in descending order of their percent contents.
The lipid/apolipoprotein ratios of LP-A-II particles from normolipidemic subjexts (2.2)and heterozygotes for ApoA-I deficiency syndromes (22) were identical. However, the reduced lipid/apolipoprotein ratio (1.3) of LP-A-I! particles from homozygous patients for ApoA-I deficiencies reflected increased apolipoprotein contents of these particles in the absence of ApoA-Icontaining lipoproteins.
lmmunochemical evidence for the heterogeneity of ApoA-iI-eontaining lipoproteins and LP-A-H particles
To identify major ApoA-il-containing lipoprotein particles, thc retained fraction from anti-ApoA-ll immur, o.,t~rber wa:, iested by crossed immunoelectrophoresis with polyclonal antisera to apolipoproteins A-I, A-II and APOB. The use of anti-ApoB in the lower gel, anti-ApoA-I in the intermediate gel and anti-ApoA-ll in the upper agarose gel (Fig. 1, panel A) revealed the presence, in normolipidemic plasma, of three distinct ApoA-ll-containing lipoprotein particles including the precipitin line of LP-A-II:B complex in the lower gel, LP-A-I:A-ll rocket in the intermediate gel and LP-A-I! rocket in the upper gel. On the other itand, in a patient homozygous for APOA-i/APOC-lli deficiency, the immunoelectrophoretic pattern (Fig. 1,  panel B) showed the presence of LP-A-II:B complex in the lower gel and LP-A-Ii in the upper gel, but the absence of LP-A-!: A-II in the intermediate gel.
The relatively high percentage contents of ApoD and ApoE in LP-A-II particles of homozygous patients with ApoA-I deficiency syndromes suggested the possible heterogeneity of this lipoprotein family, i.e., the occurrence of several LP-A-Ii subfamilies differing in their apolipoprotein composition. Testing of LP-A-I! with anti-ApoA-I and anti-ApoB sera incorporated into the lower gel and anti-ApoA-ll serum in the upper gel showed that these particles were devoid of ApoA-I and ApoB (Fig. 2, panel A) . The use of anti-APOD and anti-ApoE in the lower agarose gel and anti-ApoA-ll in the upper agarose gel revealed that LP-A-il family consisted of the so-called simple LP-A-II particles (LP-A-II particles only containing APOA-ll as their protein moiety) fi~rming a rocket in the upper gel and complex LP-A-II:D and LP-A-II:E particles precipitated as two separate lines in the lower gel (Fig.  2, panel B) . The simple LP-A-ll particles migrated faster in the first dimension than complex LP-A-II:D and LP-A-II:E particles. To provide additional evidence for the existence of LP-A-ll:D and LP-A-II: E particles, the anti-ApoE serum was incorporated into the lower gel and anti-ApoD serum in the upper gel (Fig. 2, panel C) ; ApoE-containing particles were precipitated in the lower gel and the LP-A-Ii:D particles devoid of ApoE formed a precipitin line in the intermediate gel. When the antisera were reversed (Fig. 2,  panel D) LP-A-II:D formed a precipitin line ~n the lower gel and LP-A-II : E formed a rocket in the intermediate gel. These experiments, however, have not excluded the possible, albeit unlikely, existence of LP-A-I! : D : E particles. The distribution of ApoC-peptides among these LP-A-II subfractions in homozygous patients with ApoA-I deficiency remains to be established in future experiments.
Discussion
The chemical and metabolic heterogeneity of HDL is due to the presence of discrete lipoprotein families of particles defined by their characteristic apolipoprotein composition. The application of immunoaffin. ity chromatography to the fractionation of HDL particles has resulted in the recognition and isolation ol LP-A-I and LP-A-I:A-I! as two major ApoA-l-conraining lipoprotein families. The chemical anc metabolic uniqueness of these two lipoprotein ram[lie: has been demonstrated by several independent studie~ [26] [27] [28] [29] [30] [31] [32] [33] [34] . The present report confirms and extends previous observations [37] [38] [39] [40] of a third minor Al;oA-containing lipoprotein family, LP-A-II, characterized b) ApoA-ll as its major protein constituent.
in normolipidemic subjects, the concentration ol LP-A-ll accounted for 5-20% of the total plasm~ APOA-II content not as~,~ci':ted with ApoB. A compar.
[son between the chemical characteristics of LP-A-II and LP-A-! and LP-A-I:A-ll particles isolated fron" the same normolipidemie subjects [34] In the absence of ApoA-I, the only detectable ApoA-containing lipoproteins are LP-A-il particles, the concentration of which does not differ significantly from those of normolipidemic subjects or subjects heterorygous for A-I deficiency syndromes. However, there are marked differences in the chemical composition of LP-A-ll. The lipid profile of LP-A-il from homozygous patients was characterized by a significantly higher percentage of triglycerides and a lower percentage of phospholipids in comparison with those of normal LP-A-il. The apolipoprotein composition of LP-A-II from homozygotes was characterized by a relatively high content of ApoE and, in the case of ApoA-! deficiency, presence of ApoC peptides accounting for up to 53% of the total protein mass; the protein content of ApoD was either within the normal range or markedly decreased. In hypercatabolie states such as Tangier disease, the HDL particles are quickly removed from the plasma [5t,52] which, judged from the low concentration of LP-A-II, also seems to apply to this lipoprotein family. It should be pointed out, however, that in Tangier disease the major part of ApoA-ll occurs in the LP-A-II:B complex particles of very low and low densities [361.
The presence of ApoD and other minor apolipoproteins in LP-A-II particles of normolipidemie and dyslipoproteinemic subjects suggested the possible subspecies heterogeneity of this lipeprotein family. As shown previously for LP-A-I and LP-A-I :A-ll particles [34] , minor apolipoproteins cannot be equally distributed on all LP-A-li particles, because they are not present in the same molar ratios. In normolipidemic subjects, LP-A-I! particles with ApoA-ll as the sole apolipoprotein constituent are frequently the only lipoprotein form. However, even in subjects whose LP-A-II particles contain both ApoA-ll and ApoD, the major [~poprt, tcilJ foim is the simple LP-A-ll with APOA-II as the sole protein and the minor form i~ LP-A-II:D. The crossed immunoelectrophoretic testing of ApoA-ll-containing lipoproteins in patients homozygous for ApoA-! deficiencies provided evidence for the occurrence not only of simple LP-A-II particles but also for the presence of separate LP-A-II: D and LP-A-II : E particles (Fig. 2) . The dishibution of ApoC peptides, when present, in these LP-A-I! subspecies remains to be established, it should also be pointed out that the protein moiety of LP-A-II : E subspecies mainly consists ol a rnixed disulfide complex, ApoE-ApoA-)l monomer, as previously reported for homozygous patients with ApoA-l/ApoC-lll deficiency [53] .
The origin of LP-A-II particles is not known. However, it is quite probable that these particles are formed primarily, if not exclusively, in the liver as nascent lipoproteins rich in phospholipid and free cholesterol. Fractionation of HepG2 cell medium by sequential affinity chromatography on concanavalin A and immunosorbers with anti-ApoA-ll and anti-ApoA-I resuited in the identification of a small lipoprotein fraction co~taining ApoA-li, but not ApoA-I, suggestive of LP-A-II particles (Dashti, N., personal communication) . The previously established usefulness of this cell line as a model for studying the formation of LP-A-! and LP-A-! : A-I! particles [54, 55] may prove to be equally useful for further studies on the origin and assembly of LP-A-ll particles.
At the present time we can only speculate about the possible physiologic role(s) of ApoA-containing lipoproteins including LP-A-II. It has already been suggested that LP-A-I or LP-A-I:A-IV particles may function as the acceptors of peripheral cholesterol [25, 56, 57] and LP-A-I :A-I! particles as the acceptors of lipids and apolipoproteins released during the lipolysis of triglyceride-rieh lipoproteins or, conversely, as donors of these apolipoproteins to newly secreted triglvceride-rich lipoproteins of hepatic and intestinal origin [58, 59] . Evidence presented in this study suggests that, in the absence of ApoA-I lipoproteins, LP-A-I! particles may function as substilute acceptors and donors of lipids, ApoC-peptides and ApoE taking part in processes responsible for the catabolism of triglyceride-rich lipoproteins, in fact, the capacity of LP-A-I! particles to bind and incorporate neutral lipids and minor apolipoproteins appears to be similar, if not greater, than those of LP-A-! and LP-A-I :A-ll. However, due to their relatively low plasma concentration, the LP-A-II particles may not be functionally as efticient as LP-A-I:A-ll particles, the most abundant ApoA-containing lipoprotein family. Some of the other possible roles for LP-A-ll may be to function as a precursor, in conjunction with LP-B: C: E particles, in the formation of triglyceride-rich LP-A-ll : B:C: D: E particles [36] , as modulators of hepatic triglyceride lipase [2(I-22] and lecithin:cholesterol acyltransferase [17] [18] [19] activities, as inhibitors of factor X activation [23] and as antagonists in processes responsible for the removal of cholesterol from peripheral cells [56, 57] . These possible functional roles remain to be examined in future experiments.
